A citation-based method for searching scientific literature

Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, Arun J Sanyal. Lancet 2019
Times Cited: 488







List of co-cited articles
1346 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
45

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
36

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
29

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
27

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
27

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
26

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
24

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri,[...]. Lancet 2019
224
23

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Keyur Patel, Stephen A Harrison, Magdy Elkhashab, James F Trotter, Robert Herring, Sergio E Rojter, Zeid Kayali, Vincent Wai-Sun Wong, Susan Greenbloom, Saumya Jayakumar,[...]. Hepatology 2020
124
23

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit Loomba, Mazen Noureddin, Kris V Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H Caldwell, Zachary Goodman,[...]. Hepatology 2021
77
27

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Stephen A Harrison, Guy Neff, Cynthia D Guy, Mustafa R Bashir, Angelo H Paredes, Juan P Frias, Ziad Younes, James F Trotter, Nadege T Gunn, Sam E Moussa,[...]. Gastroenterology 2021
93
21

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Sarin, Stephen H Caldwell, Naim Alkhouri,[...]. J Hepatol 2020
171
19

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
636
19

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
990
19


Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
18

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
18

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
17

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Scott L Friedman, Vlad Ratziu, Stephen A Harrison, Manal F Abdelmalek, Guruprasad P Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V Kowdley, Antonio Craxi,[...]. Hepatology 2018
393
17

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar, Robert R Henry, Arun J Sanyal, Linda Morrow, Hanns-Ulrich Marschall, Mark Kipnes, Luciano Adorini, Cathi I Sciacca, Paul Clopton, Erin Castelloe,[...]. Gastroenterology 2013
612
16

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
16

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Bradley Freilich, Muhammad Y Sheikh, Jörn M Schattenberg, Zeid Kayali, Adam Zivony,[...]. J Hepatol 2020
107
15

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, Simone I Strasser, Christopher Bowlus, Pietro Invernizzi, Joost P H Drenth, Paul J Pockros, Jaroslaw Regula, Ulrich Beuers,[...]. N Engl J Med 2016
579
15

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Kenneth Cusi, Beverly Orsak, Fernando Bril, Romina Lomonaco, Joan Hecht, Carolina Ortiz-Lopez, Fermin Tio, Jean Hardies, Celia Darland, Nicolas Musi,[...]. Ann Intern Med 2016
507
15

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Sven M Francque, Pierre Bedossa, Vlad Ratziu, Quentin M Anstee, Elisabetta Bugianesi, Arun J Sanyal, Rohit Loomba, Stephen A Harrison, Rozalina Balabanska, Lyudmila Mateva,[...]. N Engl J Med 2021
90
16

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
14

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
Naga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell Shiffman, Arun Sanyal,[...]. Gastroenterology 2020
117
14

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Stephen A Harrison, Naim Alkhouri, Beth A Davison, Arun Sanyal, Christopher Edwards, Jerry R Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman,[...]. J Hepatol 2020
100
13

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
876
13

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Vlad Ratziu, Arun Sanyal, Stephen A Harrison, Vincent Wai-Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P Aithal, Kris V Kowdley, Star Seyedkazemi, Laurent Fischer,[...]. Hepatology 2020
130
13

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, Guy Neff, Rashmee Patil, Cynthia A Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J Tillman,[...]. Nat Med 2021
51
25

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Arun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, Rohit Loomba, Stephen A Harrison, Manal F Abdelmalek, Eric J Lawitz, Dina Halegoua-DeMarzio, Sudeep Kundu, Stephanie Noviello,[...]. Lancet 2019
241
13

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Stephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, Mitchell L Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J Lawitz, Don C Rockey, Raul Aguilar Schall, Catherine Jia,[...]. Gastroenterology 2018
171
12

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V Kowdley, Michelle Lai, Eugene Schiff, Deven Parmar,[...]. Hepatology 2021
58
20

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Stephen A Harrison, Mustafa R Bashir, Kyoung-Jin Lee, Jennifer Shim-Lopez, Jonathan Lee, Brandee Wagner, Nicholas D Smith, Hubert C Chen, Eric J Lawitz. J Hepatol 2021
30
40

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric J Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M Tarrant, Bryan J McColgan,[...]. Gastroenterology 2018
171
11

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
Guillaume Lassailly, Robert Caiazzo, Line-Carolle Ntandja-Wandji, Viviane Gnemmi, Gregory Baud, Helene Verkindt, Massih Ningarhari, Alexandre Louvet, Emmanuelle Leteurtre, Violeta Raverdy,[...]. Gastroenterology 2020
156
11

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Gideon M Hirschfield, Andrew Mason, Velimir Luketic, Keith Lindor, Stuart C Gordon, Marlyn Mayo, Kris V Kowdley, Catherine Vincent, Henry C Bodhenheimer, Albert Parés,[...]. Gastroenterology 2015
368
11

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
Roberto Pellicciari, Stefano Fiorucci, Emidio Camaioni, Carlo Clerici, Gabriele Costantino, Patrick R Maloney, Antonio Morelli, Derek J Parks, Timothy M Willson. J Med Chem 2002
547
11

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Paul J Pockros, Michael Fuchs, Bradley Freilich, Eugene Schiff, Anita Kohli, Eric J Lawitz, Paul A Hellstern, Janet Owens-Grillo, Courtney Van Biene, Reshma Shringarpure,[...]. Liver Int 2019
73
15

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Rohit Loomba, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, C Stephen Djedjos, Ling Han, Robert P Myers,[...]. Hepatology 2018
344
10

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
625
10

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
875
10

Treatment of NAFLD with diet, physical activity and exercise.
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. J Hepatol 2017
527
10

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
10

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Fernando Bril, Diane M Biernacki, Srilaxmi Kalavalapalli, Romina Lomonaco, Sreevidya K Subbarayan, Jinping Lai, Fermin Tio, Amitabh Suman, Beverly K Orsak, Joan Hecht,[...]. Diabetes Care 2019
134
10

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew Muir, Simon Rushbrook,[...]. Hepatology 2019
119
10

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.
Takeshi Inagaki, Mihwa Choi, Antonio Moschetta, Li Peng, Carolyn L Cummins, Jeffrey G McDonald, Guizhen Luo, Stacey A Jones, Bryan Goodwin, James A Richardson,[...]. Cell Metab 2005
10

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
263
10

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Keith D Lindor, Kris V Kowdley, E Jenny Heathcote, M Edwyn Harrison, Roberta Jorgensen, Paul Angulo, James F Lymp, Lawrence Burgart, Patrick Colin. Hepatology 2004
493
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.